Over the past few years, immunotherapy has radically changed the management of advanced non-small cell lung cancer (NSCLC). More recently, this paradigm shift has extended into early-stage resectable disease. A series of landmark trials have demonstrated that the addition of immune checkpoint inhibitors (ICIs) in the perioperative setting, i.e. both before (neoadjuvant) and after (adjuvant) surgery, can significantly improve long-term outcomes. This article reviews the latest evidence supporting perioperative immunotherapy in resectable NSCLC.
